Deal Watch Alexion Encouraged By RNAi Developments Partners With Dicerna

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration...

More From BioPortfolio on "Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna"